Cargando…
French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study
INTRODUCTION: There is a dearth of evidence to document treatment of FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) in real-world settings before the introduction of FLT3 inhibitors. A retrospective cohort study was conducted to understand treatment practices prior to the ava...
Autores principales: | Garnham, Andy, Bruon, Franck, Berthon, Céline, Lebon, Delphine, Parimi, Mounika, Polya, Rosalind, Makhloufi, Kahina M., Dramard-Goasdoue, Marie-Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447689/ https://www.ncbi.nlm.nih.gov/pubmed/37578642 http://dx.doi.org/10.1007/s40487-023-00239-2 |
Ejemplares similares
-
Loss of MiR-155 Sensitizes FLT3-ITD(+)AML to Chemotherapy and FLT3 Inhibitors via Glycolysis Blocking by Targeting PIK3R1
por: Wang, Lingyan, et al.
Publicado: (2023) -
UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017) -
Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022) -
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
por: Perl, Alexander E., et al.
Publicado: (2022) -
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)